Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
ADAPT PHARMA OPERATIONS LIMITED et al v. TEVA PHARMACEUTICALS USA, INC. et al
Case Number:
2:16-cv-07721
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
June 23, 2020
Obviousness Doomed Narcan Patents After NJ Bench Trial
Teva Pharmaceuticals proved that claims from four patents covering Adapt Pharma's opioid overdose medication Narcan are obvious, and the drug's success can't override that finding, a New Jersey federal judge said in an opinion unsealed Monday.
-
June 05, 2020
Teva Invalidates Opiant Patents In Narcan Suit
A New Jersey federal judge found that claims from four patents related to Narcan, the nasal spray treatment for opioid overdoses, are invalid Friday, handing a win to Teva Pharmaceuticals USA Inc. in a suit from the treatment's licensor and licensee Opiant Pharmaceuticals Inc. and Adapt Pharma Operations Ltd.
-
October 24, 2016
Teva's Generic Overdose Drug Application Sparks IP Suit
Irish drugmaker Adapt Pharma Operations Ltd. sued Teva Pharmaceuticals USA Inc. in New Jersey federal court Friday, saying that Teva's application to sell a generic version of Adapt's Narcan nasal spray treatment for opioid overdoses infringes the drug's patent.